GlassScriptPhysician profile
Cecilia Berumen
NPI 1548621642
$2,159.89
in general payments reported to CMS, 2019-2025
17 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,052 · 2022: $538 · 2023: $204 · 2024: $172 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520 · Education: $49.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.70 |
| Education | $49.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $769.40 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $373.72 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $227.42 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.52 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.72 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $82.96 | 2021-2024 | Spravato |
| Corium, LLC | $79.31 | 2023-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $77.29 | 2021-2024 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $54.74 | 2021 | |
| Lundbeck LLC | $52.33 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $36.00 | 2021-2025 | Rexulti |
| Almatica Pharma LLC | $23.31 | 2021 | |
| Lilly USA, LLC | $17.96 | 2021 | |
| Adlon Therapeutics L.P. | $16.53 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.20 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.85 | 2021 | |
| Indivior INC. | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Berumen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.